ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
ProKidney will present eight abstracts, including one oral presentation, on rilparencel at ASN Kidney Week 2026 (October 21-25, Denver). A new pooled Phase 2 analysis in patients meeting key PROACT 1 inclusion criteria continues to show a strong safety profile and kidney function stabilization in advanced CKD patients with type 2 diabetes.
Key figures
- Drug Name
- rilparencel (REACT)
- Phase Of Trial
- Phase 3 (PROACT 1); new pooled Phase 2 analysis
- Abstracts accepted
- 8
- Oral presentations
- 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.